Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

doi:10.1158/0008-5472.CAN-21-1256

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

Cancer research - 15 Dec 2021

Gou Xuxu, Anurag Meenakshi, Lei Jonathan T, Kim Beom-Jun, Singh Purba, Seker Sinem, Fandino Diana, Han Airi, Rehman Saif, Hu Jianhong, Korchina Viktoriya, Doddapaneni Harshavardhan, Dobrolecki Lacey E, Mitsiades Nicholas, Lewis Michael T, Welm Alana L, Li Shunqiang, Lee Adrian V, Robinson Dan R, Foulds Charles E, Ellis Matthew J

Abstract excerpt

Genomic analysis has recently identified multiple ESR1 gene translocations in estrogen receptor alpha-positive (ERα+) metastatic breast cancer (MBC) that encode chimeric proteins whereby the ESR1 ligand binding domain (LBD) is replaced by C-terminal sequences from many different gene partners. Here we functionally screened 15 ESR1 fusions and identified 10 that promoted estradiol-independent cell growth,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Estrogen Receptor alpha

Share to Mice, Nude

Share to Oncogene Proteins, Fusion

Share to Survival Rate

Share to Transcriptome

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34711608
DOI: 10.1158/0008-5472.CAN-21-1256
PMCID: PMC9234971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.PMID 34711608Read ↗

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Semantic proximity Read ↗

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.Semantic proximity Read ↗

Molecular characterization of ESR1 variants in breast cancer.Semantic proximity Read ↗

ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesSemantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

ERα-LBD, a novel isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistanceSemantic proximity Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.Semantic proximity Read ↗

Fusion Genes in Breast Cancer.Semantic proximity Read ↗

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasisSemantic proximity Read ↗

ESR1 activating mutations: From structure to clinical application.Semantic proximity Read ↗

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.